{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:15Z","timestamp":1758937215576,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002361","name":"Brazilian Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.leukres.2021.106689","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T10:48:59Z","timestamp":1631702939000},"page":"106689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-4309","authenticated-orcid":false,"given":"Jaqueline","family":"Sapelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayr Schmidt","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garles Miller","family":"Matias Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Lemos","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janaina Naiara","family":"Germano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-1101","authenticated-orcid":false,"given":"Vladmir Cl\u00e1udio Cordeiro","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.leukres.2021.106689_bib0005","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"8852","key":"10.1016\/j.leukres.2021.106689_bib0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.leukres.2021.106689_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1634\/theoncologist.2011-0177","article-title":"Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma","volume":"17","author":"Colpo","year":"2012","journal-title":"Oncologist [Internet]"},{"issue":"10","key":"10.1016\/j.leukres.2021.106689_bib0020","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1200\/JCO.1993.11.10.1846","article-title":"High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive Non-Hodgkin\u2019s lymphoma","volume":"11","author":"Vose","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2021.106689_bib0025","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.1990.8.5.784","article-title":"Autologous bone marrow transplantation in B-cell non-Hodgkin\u2019s lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse","volume":"8","author":"Freedman","year":"1990","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2021.106689_bib0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.bmt.1705841","article-title":"Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu\/Cy\/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"40","author":"Kim","year":"2007","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.leukres.2021.106689_bib0035","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/sj.bmt.1701245","article-title":"Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy","volume":"21","author":"Kroger","year":"1998","journal-title":"Bone Marrow Transplant. [Internet]"},{"issue":"7","key":"10.1016\/j.leukres.2021.106689_bib0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","article-title":"High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma","volume":"34","author":"Wang","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.leukres.2021.106689_bib0045","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428190500527769","article-title":"Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation","volume":"47","author":"Puig","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2021.106689_bib0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bmt.2016.340","article-title":"Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review","volume":"52","author":"Damaj","year":"2017","journal-title":"Bone Marrow Transplant. [Internet]"},{"issue":"12","key":"10.1016\/j.leukres.2021.106689_bib0055","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.bmt.1702433","article-title":"Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin\u2019s lymphoma","volume":"25","author":"Copelan","year":"2000","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.leukres.2021.106689_bib0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.leukres.2021.106689_bib0065","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2021.106689_bib0070","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) - Version 5.0","first-page":"3","author":"U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES","year":"2017"},{"issue":"23","key":"10.1016\/j.leukres.2021.106689_bib0075","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive Non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"Jan. (1)","key":"10.1016\/j.leukres.2021.106689_bib0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.1999.17.1.222","article-title":"Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin\u2019s disease induction failure: a case-control study. Soci\u00e9t\u00e9 Francaise de Greffe de Moelle","volume":"17","author":"Andr\u00e9","year":"1999","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"Feb. (2)","key":"10.1016\/j.leukres.2021.106689_bib0085","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","article-title":"Autotransplants for Hodgkin\u2019s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"17","author":"Lazarus","year":"1999","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"May (9)","key":"10.1016\/j.leukres.2021.106689_bib0090","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1200\/JCO.2002.09.138","article-title":"Autologous transplantation for aggressive non-Hodgkin\u2019s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease","volume":"20","author":"Vose","year":"2002","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"2","key":"10.1016\/j.leukres.2021.106689_bib0095","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"19","author":"Vose","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2021.106689_bib0100","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.2020007939","article-title":"Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?","volume":"137","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106689_bib0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","author":"Albinger","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.leukres.2021.106689_bib0110","unstructured":"U.S. Food & Drug Administrations. KYMRIAH (tisagenlecleucel). [Internet]. Available from: https:\/\/www.fda.gov\/vaccines-blood biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"key":"10.1016\/j.leukres.2021.106689_bib0115","unstructured":"U.S. Food & Drug Administrations. Yescarta (axicabtagene ciloleucel). (2020) https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel."},{"key":"10.1016\/j.leukres.2021.106689_bib0120","unstructured":"U.S. Food & Drug Administrations. TECARTUS (brexucabtagene autoleucel). (2020) https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel."},{"issue":"2","key":"10.1016\/j.leukres.2021.106689_bib0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00277-001-0413-8","article-title":"Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma","volume":"81","author":"H\u00e4nel","year":"2002","journal-title":"Ann. Hematol."},{"issue":"Feb. (2)","key":"10.1016\/j.leukres.2021.106689_bib0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7326\/0003-4819-104-2-163","article-title":"High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin\u2019s disease","volume":"104","author":"Jagannath","year":"1986","journal-title":"Ann. Intern. Med. [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2021.106689_bib0135","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"Dec. (12)","key":"10.1016\/j.leukres.2021.106689_bib0140","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.1994.12.12.2559","article-title":"High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma","volume":"12","author":"Weaver","year":"1994","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.leukres.2021.106689_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008397220178","article-title":"International consensus conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive Non-Hodgkin\u2019s lymphomas: report of the jury","volume":"10","author":"Shipp","year":"1999","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2021.106689_bib0150","article-title":"Hematopoietic stem cell transplantation\u201450 years of evolution and future perspectives","volume":"5","author":"Henig","year":"2014","journal-title":"Rambam Maimonides Med. J. [Internet]"},{"issue":"September","key":"10.1016\/j.leukres.2021.106689_bib0155","article-title":"Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras","author":"Li","year":"2019","journal-title":"Bone Marrow Transplant. [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2021.106689_bib0160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bmt.2008.336","article-title":"Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit","volume":"43","author":"Trinkaus","year":"2009","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.leukres.2021.106689_bib0165","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2016.03.018","article-title":"Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase 2 study and CIBMTR outcomes","volume":"22","author":"Flowers","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.leukres.2021.106689_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.01.032","article-title":"BEAM versus BUCYVP16 conditioning before autologous hematopoietic stem cell transplant in patients with hodgkin lymphoma","author":"Singer","year":"2019","journal-title":"Biol. Blood Marrow Transplant. [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2021.106689_bib0175","first-page":"839","article-title":"Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative\/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient","volume":"27","author":"Eduardo","year":"2019","journal-title":"Support. Care Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2021.106689_bib0180","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41409-019-0521-5","article-title":"Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study","volume":"54","author":"Esteves","year":"2019","journal-title":"Bone Marrow Transplant. [Internet]"},{"issue":"Feb. (2)","key":"10.1016\/j.leukres.2021.106689_bib0185","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","article-title":"BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: a single center comparative analysis of efficacy and toxicity","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk. Res. [Internet]"},{"issue":"12","key":"10.1016\/j.leukres.2021.106689_bib0190","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2006.08.039","article-title":"Long-term outcome of hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation","volume":"12","author":"Wadehra","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"11","key":"10.1016\/j.leukres.2021.106689_bib0195","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S2352-3026(18)30171-6","article-title":"Is pharmacokinetic guidance a must in busulfan regimens?","volume":"5","author":"Kanda","year":"2018","journal-title":"Lancet Haematol. [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2021.106689_bib0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF00686238","article-title":"Clinical pharmacodynamics of continuous-infusion etoposide","volume":"25","author":"Miller","year":"1990","journal-title":"Cancer Chemother. Pharmacol. [Internet]"},{"issue":"3","key":"10.1016\/j.leukres.2021.106689_bib0205","first-page":"246","article-title":"In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy","volume":"19","author":"Wolff","year":"1987","journal-title":"Cancer Chemother. Pharmacol. [Internet]"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:43Z","timestamp":1758934963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621001909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":41,"alternative-id":["S0145212621001909"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106689","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106689"}}